This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (28)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Otolaryngology/ Head & Neck Surgery  • Endocrine Surgery  • Alert me on articles by topic

John R. Burgess, MB, BS, FRACP; Rueben David; Venkateswaran Parameswaran, PhD; Tim M. Greenaway, PhD, FRACP; Joseph J. Shepherd, FRACS

Arch Surg. 1998;133:126-129.

Background  The efficacy of subtotal parathyroidectomy for the treatment of hyperparathyroidism in multiple endocrine neoplasia type 1 (MEN 1) is unclear. The long-term outcome and optimal timing of operation remain controversial.

Objective  To determine the long-term outcome of parathyroidectomy for primary hyperparathyroidism in the presence of MEN 1.

Design  Case series and retrospective analysis.

Setting  Tertiary referral center.

Patients  Patients with MEN 1 from 2 families.

Interventions  Subtotal parathyroidectomy, ie, resection of 3 parathyroid glands from each patient.

Main Outcome Measures  Recurrence of hyperparathyroidism.

Results  Thirty-seven patients underwent subtotal parathyroidectomy. Overall, persistent postoperative hypoparathyroidism developed in 24%, normocalcemia was maintained in 46%, and hyperparathyroidism recurred in 30%. However, after adjustment for the duration of follow-up (by using the Kaplan-Meier method), the cumulative recurrence rates for hyperparathyroidism were 15% at 2 years, 23% at 4 years, 55% at 8 years, and 67% after 8 years. Early recurrence of hyperparathyroidism (within 5 years of operation) was less likely to develop in patients in whom ionized calcium levels of 1.00 mmol/L (4.00 mg/dL) or less were achieved during the perioperative period than in patients in whom this degree of hypocalcemia failed to develop (P=.01).

Conclusions  While relatively long periods of disease remission are possible after subtotal parathyroidectomy, our results indicate that recurrent hyperparathyroidism eventually develops in most patients with MEN 1.

From the Departments of Diabetes and Endocrine Services (Drs Burgess, Parameswaran, and Greenaway) and Clinical Chemistry (Mr David), Royal Hobart Hospital, Hobart, and the Department of Surgery (Dr Shepherd), University of Tasmania, Tasmania, Australia.

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Percutaneous Parathyroid Ethanol Ablation in Patients with Multiple Endocrine Neoplasia Type 1
Veldman et al.
Am. J. Roentgenol. 2008;191:1740-1744.
ABSTRACT | FULL TEXT  

Subtotal parathyroidectomy as an adequate treatment for primary hyperparathyroidism in multiple endocrine neoplasia type 1.
Hubbard et al.
Arch Surg 2006;141:235-239.
ABSTRACT | FULL TEXT  

Primary Hyperparathyroidism in Multiple Endocrine Neoplasia Type 1: Individualized Management With Low Recurrence Rates
Lee et al.
Ann. Surg. Oncol. 2006;13:103-109.
ABSTRACT | FULL TEXT  

Osteoporosis in Multiple Endocrine Neoplasia Type 1: Severity, Clinical Significance, Relationship to Primary Hyperparathyroidism, and Response to Parathyroidectomy
Burgess et al.
Arch Surg 1999;134:1119-1123.
ABSTRACT | FULL TEXT